Company registration number 10752335 (England and Wales)
IMPETUS PHARMA LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025
PAGES FOR FILING WITH REGISTRAR
IMPETUS PHARMA LIMITED
COMPANY INFORMATION
Director
Mrs LC Burbidge
Company number
10752335
Registered office
Garthwaite
Crawley Hill
West Wellow
United Kingdom
SO51 6AP
Accountants
Xeinadin
First Floor Secure House
Lulworth Close
Chandler's Ford
Eastleigh
Hampshire
England
SO53 3TL
IMPETUS PHARMA LIMITED
CONTENTS
Page
Director's report
1
Accountants' report
2
Balance sheet
3 - 4
Notes to the financial statements
5 - 7
IMPETUS PHARMA LIMITED
DIRECTOR'S REPORT
FOR THE YEAR ENDED 31 MAY 2025
- 1 -

The director presents her annual report and financial statements for the year ended 31 May 2025.

Director

The director who held office during the year and up to the date of signature of the financial statements was as follows:

Mrs LC Burbidge
Small companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the board
Mrs LC Burbidge
Director
21 January 2026
IMPETUS PHARMA LIMITED
ACCOUNTANTS' REPORT TO THE DIRECTOR ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF IMPETUS PHARMA LIMITED FOR THE YEAR ENDED 31 MAY 2025
- 2 -

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Impetus Pharma Limited for the year ended 31 May 2025 which comprise, the balance sheet and the related notes from the company’s accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com/regulation.

This report is made solely to the b oard of d irectors of Impetus Pharma Limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of Impetus Pharma Limited and state those matters that we have agreed to state to the b oard of d irectors of Impetus Pharma Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Impetus Pharma Limited and its b oard of d irectors as a body, for our work or for this report.

It is your duty to ensure that Impetus Pharma Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Impetus Pharma Limited. You consider that Impetus Pharma Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Impetus Pharma Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory f inancial statements.

Xeinadin
First Floor Secure House
Lulworth Close
Chandler's Ford
Eastleigh
Hampshire
SO53 3TL
England
21 January 2026
IMPETUS PHARMA LIMITED
BALANCE SHEET
AS AT
31 MAY 2025
31 May 2025
- 3 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
9,296
11,895
Current assets
Debtors
331
33
Cash at bank and in hand
201,034
182,962
201,365
182,995
Creditors: amounts falling due within one year
4
(21,377)
(16,338)
Net current assets
179,988
166,657
Total assets less current liabilities
189,284
178,552
Creditors: amounts falling due after more than one year
5
-
0
(14,471)
Provisions for liabilities
(2,324)
(2,260)
Net assets
186,960
161,821
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
186,860
161,721
Total equity
186,960
161,821
IMPETUS PHARMA LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 MAY 2025
31 May 2025
- 4 -

For the financial year ended 31 May 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 21 January 2026
Mrs LC Burbidge
Director
Company registration number 10752335 (England and Wales)
IMPETUS PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025
- 5 -
1
Accounting policies
Company information

Impetus Pharma Limited is a private company limited by shares incorporated in England and Wales. The registered office is Garthwaite, Crawley Hill, West Wellow, United Kingdom, SO51 6AP.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

The company recognises revenue from the following major sources:

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computers
25% on reducing balance
Motor vehicles
25% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

IMPETUS PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2025
1
Accounting policies
(Continued)
- 6 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.5
Retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

1.6
Leases
As lessee

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
1
1
IMPETUS PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2025
- 7 -
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 June 2024
38,588
Additions
499
At 31 May 2025
39,087
Depreciation and impairment
At 1 June 2024
26,693
Depreciation charged in the year
3,098
At 31 May 2025
29,791
Carrying amount
At 31 May 2025
9,296
At 31 May 2024
11,895
4
Creditors: amounts falling due within one year
2025
2024
£
£
Taxation and social security
17,147
7,690
Other creditors
4,230
8,648
21,377
16,338
5
Creditors: amounts falling due after more than one year
2025
2024
£
£
Other creditors
-
0
14,471
2025-05-31 2024-06-01 false false false 21 January 2026 CCH Software CCH Accounts Production 2025.300 No description of principal activity Mrs LC Burbidge 10752335 2024-06-01 2025-05-31 10752335 bus:Director1 2024-06-01 2025-05-31 10752335 bus:RegisteredOffice 2024-06-01 2025-05-31 10752335 2025-05-31 10752335 2024-05-31 10752335 core:OtherPropertyPlantEquipment 2025-05-31 10752335 core:OtherPropertyPlantEquipment 2024-05-31 10752335 core:WithinOneYear 2025-05-31 10752335 core:WithinOneYear 2024-05-31 10752335 core:AfterOneYear 2025-05-31 10752335 core:AfterOneYear 2024-05-31 10752335 core:CurrentFinancialInstruments 2025-05-31 10752335 core:CurrentFinancialInstruments 2024-05-31 10752335 core:ShareCapital 2025-05-31 10752335 core:ShareCapital 2024-05-31 10752335 core:RetainedEarningsAccumulatedLosses 2025-05-31 10752335 core:RetainedEarningsAccumulatedLosses 2024-05-31 10752335 core:ComputerEquipment 2024-06-01 2025-05-31 10752335 core:MotorVehicles 2024-06-01 2025-05-31 10752335 2023-06-01 2024-05-31 10752335 core:OtherPropertyPlantEquipment 2024-05-31 10752335 core:OtherPropertyPlantEquipment 2024-06-01 2025-05-31 10752335 core:Non-currentFinancialInstruments 2025-05-31 10752335 core:Non-currentFinancialInstruments 2024-05-31 10752335 bus:PrivateLimitedCompanyLtd 2024-06-01 2025-05-31 10752335 bus:SmallCompaniesRegimeForAccounts 2024-06-01 2025-05-31 10752335 bus:FRS102 2024-06-01 2025-05-31 10752335 bus:AuditExemptWithAccountantsReport 2024-06-01 2025-05-31 10752335 bus:FullAccounts 2024-06-01 2025-05-31 xbrli:pure xbrli:shares iso4217:GBP